Encova insurance deploys Sapiens’ automated testing services

Published 10/09/2025, 12:16
Encova insurance deploys Sapiens’ automated testing services

ROCHELLE PARK, N.J. - Sapiens International Corporation (NASDAQ:SPNS), a software solutions provider with a market capitalization of $2.4 billion and strong financial health according to InvestingPro metrics, announced Wednesday the first implementation of its Automated Testing Services (ATS) with Encova Insurance for workers’ compensation operations.

The deployment aims to shorten testing cycles for Encova’s existing CoreSuite for Workers’ Compensation solution. According to the company’s press release, the service will help reduce time-intensive regression testing for system upgrades that previously impacted Encova’s ability to execute new releases frequently. This initiative comes as Sapiens maintains steady growth, with revenue increasing 3.08% over the last twelve months.

The implementation began in April 2025, with the first automated tests scheduled to support Encova’s next upgrade in October. The service utilizes Microsoft Playwright testing tool integrated with a custom framework developed by Sapiens.

"Sapiens’ ATS will reduce our testing effort, improve the quality of our releases, and free us up for business-critical and strategic priorities," said Ramu Lingala, Encova Executive Vice President and Chief Information Officer.

Sapiens’ ATS provides Encova with access to pre-built automated regression test suites that are regularly updated with each product release. The service also includes customized test cases tailored to Encova’s operational environment.

Encova Insurance is a multi-line mutual insurer serving the Midwest and Mid-Atlantic regions, with over 1,100 associates writing in 27 states and Washington, D.C.

Sapiens International Corporation, a provider of software solutions for the insurance industry, announced on August 12, 2025, that it entered into a definitive agreement to be acquired by Advent, a private equity investor, for $43.50 per common share in cash, valuing Sapiens at approximately $2.5 billion. The stock currently trades near its 52-week high of $43.11, with InvestingPro analysis suggesting a premium valuation with a P/E ratio of 35.11. Subscribers can access 10+ additional ProTips and comprehensive financial metrics on the platform.

In other recent news, Sapiens International Corporation announced the deployment of its Automated Testing Services with Encova Insurance. This implementation is intended to streamline the testing cycles for Encova’s CoreSuite for Workers’ Compensation solution, reducing the time needed for regression testing during system upgrades. Additionally, Sapiens has launched version 13.0 of its CoreSuite for Property & Casualty, which is targeted at the North American insurance market. The new version includes a configurable dashboard that provides underwriters with real-time workload visibility, along with enhancements to its ClaimsPro, BillingPro, and PolicyPro solutions. These updates aim to improve operational efficiencies and the user experience for all North American CoreSuite for P&C customers.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.